Clinical Trial Detail

NCT ID NCT02164916
Title S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Southwest Oncology Group
Indications

colon adenocarcinoma

rectum adenocarcinoma

Therapies

Cetuximab + Irinotecan

Cetuximab + Irinotecan + Vemurafenib

Age Groups: adult

Additional content available in CKB BOOST